Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): A phase I dose-finding study

Veterinary and Comparative Oncology

Volumn 10, Issue 3, 2012, Pages 184-193

  Chon, E ^a   Mccartan, L ^a   Kubicek, L N ^a   Vail, D M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Chemotherapy; Non steroidal anti inflammatory drugs; Oncology; Tumour biology; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; TOCERANIB;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; DOG; DOG DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; GASTROINTESTINAL DISEASE; MALE; NEOPLASM; PHASE 1 CLINICAL TRIAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; INDOLES; MALE; NEOPLASMS; PIROXICAM; PROTEIN-TYROSINE KINASES; PYRROLES;

CANIS FAMILIARIS;

EID: 84864862751     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00265.x     Document Type: Article

References (48)

1. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN and Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009; 15: 3856-3865.
2. Millanta F, Caneschi V, Ressel L, Citi A and Poli A. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. Journal of Comparative Pathology 2009; 142: 36-42.
3. Maiolino P, De Vico G and Restucci B. Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. Journal of Comparative Pathology 2000; 123: 141-145.
4. Restucci B, Papparella S, Maiolino P and De Vico G. Expression of vascular endothelial growth factor in canine mammary tumors. Veterinary Pathology 2002; 39: 488-493.
5. Millanta F, Silvestri G, Vaselli C, Citi S, Pisani G, Lorenzi D and Poli A. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. Research in Veterinary Science 2006; 81: 350-357.
6. Shiomitsu K, Johnson CL, Malarkey DE, Pruitt AF and Thrall DE. Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Veterinary & Comparative Oncology 2009; 7: 106-114.
7. Al-Dissi AN, Haines DM, Singh B and Kidney BA. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas. Veterinary Pathology 2007; 44: 823-830.
8. Yonemaru K, Sakai H, Murakami M, Yanai T and Masegi T. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Veterinary Pathology 2006; 43: 971-980.
9. Platt SR, Scase TJ, Adams V, Wieczorek L, Miller J, Adamo F and Long S. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. Journal of Veterinary Internal Medicine 2006; 20: 663-668.
10. Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG and Valent P. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Veterinary Immunology and Immunopathology 2007; 115: 320-333.
11. Al-Dissi AN, Haines DM, Singh B and Kidney BA. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas. Journal of Comparative Pathology 2009; 51: 1109-1114.
12. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G and Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003; 9: 2755-2768.
13. Schmidt BR, Glickman NW, DeNicola DB, de Gortari AE and Knapp DW. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 2001; 218: 1783-1786.
14. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, Defortari AE, Bonney PL and Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Research 2002; 62: 356-358.
15. Knapp DW, Richardson RC, Chan TC, Bottoms GD, Widmer WR, DeNicola DB, Teclaw R, Bonney PL, Kuczek T. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine 1994; 8: 273-278.
16. Sorenmo KU, Goldschmidt MH, Shofer FS, Goldkamp C and Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Veterinary & Comparative Oncology 2004; 2: 13-23.
17. Elmslie RE, Glawe P and Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. Journal of Veterinary Internal Medicine 2008; 22: 1373-1379.
18. Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P and Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of Veterinary Internal Medicine 2007; 21: 764-769.
19. Streppa HK, Jones CJ and Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. American Journal of Veterinary Research 2002; 63: 91-94.
20. Knottenbelt C, Chambers G, Gault E and Argyle DJ. The in vitro effects of piroxicam and meloxicam on canine cell lines. Journal of Small Animal Practice 2006; 47: 14-20.
21. Heller DA, Clifford CA, Goldschmidt MH, Holt DE, Shofer FS, Smith A and Sorenmo KU. Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Veterinary Pathology 2005; 42: 776-780.
22. Khan KN, Stanfield KM, Trajkovic D and Knapp DW. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Veterinary Pathology 2001; 38: 116-119.
23. Lee JY, Tanabe S, Shimohira H, Kobayashi Y, Oomachi T, Azuma S, Ogihara K and Inokuma H. Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. Research in Veterinary Science 2007; 83: 210-216.
24. Borzacchiello G, Russo V and Russo M. Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas. Journal of Veterinary Medicine Series A Physiology Pathology Clinical Medicine 2007; 54: 247-249.
25. Impellizeri JA and Esplin DG. Expression of cyclooxygenase-2 in canine nasal carcinomas. Veterinary Journal 2008; 176: 408-410.
26. Pronovost N, Suter MM, Mueller E, Sirois J and Dore M. Expression and regulation of cyclooxygenase-2 in normal and neoplastic canine keratinocytes. Veterinary & Comparative Oncology 2004; 2: 222-233.
27. McEntee MF, Cates JM and Neilsen N. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Veterinary Pathology 2002; 39: 428-436.
28. Rossmeisl JH Jr, Robertson JL, Zimmerman KL, Higgins MA and Geiger DA. Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas. Veterinary & Comparative Oncology 2009; 7: 173-180.
29. Paglia D, Dubielzig RR, Kado-Fong HK and Maggs DJ. Expression of cyclooxygenase-2 in canine uveal melanocytic neoplasms. American Journal of Veterinary Research 2009; 70: 1284-1290.
30. Mullins MN, Lana SE, Dernell WS, Ogilvie GK, Withrow SJ and Ehrhart EJ. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. Journal of Veterinary Internal Medicine 2004; 18: 859-865.
31. Pires I, Garcia A, Prada J and Queiroga FL. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours. Journal of Comparative Pathology 2010; 143: 142-149.
32. Mansa S, Palmer E, Grondahl C, Lonaas L and Nyman G. Long-term treatment with carprofen of 805 dogs with osteoarthritis. Veterinary Record 2007; 160: 427-430.
33. Pollmeier M, Toulemonde C, Fleishman C and Hanson PD. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Veterinary Record 2006; 159: 547-551.
34. Aragon CL, Hofmeister EH and Budsberg SC. Systematic review of clinical trials of treatments for osteoarthritis in dogs. Journal of the American Veterinary Medical Association 2007; 230: 514-521.
35. Dick WC, Bulstra S, Schardijn GH and Feenstra RM. Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee. Clinical Therapy 1992; 14: 517-526.
36. Dick WC, Franchimont P and Veys E. Double-blind comparison of etodolac and piroxicam in the treatment of rheumatoid arthritis. Clinical Therapy 1993; 15: 148-59.
37. Lightfoot R. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. Journal of Rheumatology Supplement 1997; 47: 10-16.
38. Knapp DW, Richardson RC, Bottoms GD, Teclaw R and Chan TC. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemotherapy and Pharmacology 1992; 29: 214-218.
39. Fox LE, Rosenthal RC, Twedt DC, Dubielzig RR, MacEwen EG and Grauer GF. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. Journal of Veterinary Internal Medicine 1990; 4: 242-246.
40. Howard EB, Sawa TR, Nielsen SW and Kenyon AJ. Mastocytoma and gastroduodenal ulceration: gastric and duodenal ulcers in dogs with mastocytoma. Pathologia Veterinaria 1969; 6: 146-158.
41. Vail DM. Cancer clinical trials: development and implementation. Veterinary Clinical North American Small Animal Practice 2007; 37: 1033-1057.
42. Lynch S, Savary-Bataille K, de Leeuw B and Argyl D. Development of a questionnaire assessing health related quality of life in dogs and cats with cancer. Veterinary & Comparative Oncology 2010; doi:10.1111/j.1476-5829.2010.00244.x.
43. Veterinary Co-operative Oncology Group. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary & Comparative Oncology 2004; 2: 195-213.
44. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009; 45: 228-247.
45. Roth SH and Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Archives of Internal Medicine 1987; 147: 2093-2100.
46. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney International 1993; 44: 643-653.
47. Boria PA, Glickman NW, Schmidt BR, Widmer WR, Mutsaers AJ, Adams LG, Snyder PW, DiBernardi L, de Gortari AE, Bonney PL and Knapp DW. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Veterinary & Comparative Oncology 2005; 3: 73-80.
48. Papich MG. An update on non-steroidal anti-inflammatory drugs (NSAIDs) in small animals. Veterinary Clinical Small Animal 2008; 38: 1243-1266.